Insys Therapeutics Up On Bullish Analyst Initiation
Specialty drugmaker Insys Therapeutics (INSY) was up 4% in morning trading on the stock market today after RBC Capital Markets launched coverage with an outperform rating. Analyst Randall Stanicky pointed to the strong launch of Subsys, a spray form of fentanyl used to rapidly treat pain in cancer patients. He predicted that by 2020 it could have 40% share of its niche, saying that it’s meaningfully different from Teva Pharmaceutical Industries’